CFO
MRSN

Callan Family Office’s Mersana Therapeutics MRSN Stock Holding History

Callan Family Office’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,262
Closed -$16.7K – 914
2025
Q2 		$16.7K Buy
+2,262
New +$19.9K ﹤0.01% 917

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Callan Family Office's MRSN Position: Q3 2025 in Review

Callan Family Office sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 2,262 shares — an estimated $16.7K sold.

Callan Family Office first reported a position in MRSN in Q2 2025 and held it in 1 quarter. The position peaked at $16.7K in Q2 2025. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Callan Family Office reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Callan Family Office sold 2,262 Mersana Therapeutics shares in Q3 2025, an estimated $16.7K.
  • Callan Family Office first reported a position in Mersana Therapeutics in Q2 2025 and held it in 1 quarter.
  • Callan Family Office's Mersana Therapeutics position peaked at $16.7K in Q2 2025.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Callan Family Office's 13F filing for Q3 2025, filed 4 Nov 2025.